Pro members get same-minute coverage on the stocks they track. Free plans update twice a day.
Get ProCounts of positive, neutral, and negative news items. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
The items moving the net sentiment the most, by direction and influence.
CMS Drug Price Rule May Target Subcutaneous Keytruda and Opdivo, Hitting Merck and Bristol Myers
Direct news · High influence · Long term
CMS Proposes Extending Medicare Drug Price Negotiations to 2029, Pressuring Big Pharma Revenue
Drug pricing / FDA / IRA · High influence · Long term
Merck Stock: Physicians Say They Are Ready to Prescribe Its Oral PCSK9 Pill
Direct news · Medium influence · Short term
Merck Stock Jumps on FDA Approval of New Cholesterol Pill
Direct news · Medium influence · Long term
Merck's Lipfendra Cholesterol Pill Gets FDA Approval: Stock Implications
Direct news · Medium influence · Long term
Macro, commodity, FX and regulatory forces that moved MRK in this range, with the stories behind each.
Also monitored for MRK (no news in this range): FDA approvals & trial outcomes.
Sign up free to track MRK, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track MRK for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Merck's Lipfendra Cholesterol Pill Gets FDA Approval: Stock Implications
How news sentiment on Merck & Co. (MRK) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
